To tackle the ongoing high burden of hepatitis C virus (HCV) infections among people who inject drugs (PWID), WHO has set a specific incidence target among PWID of no more than two new infections per ...
HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in ...
In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, researchers have identified a vulnerability that opens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback